„Vielversprechende personalisierte Krebsimpfstoffe waren ein wiederkehrendes Thema auf der Jahrestagung der American Association for Cancer Research (AACR) Anfang dieses Monats in San Diego. Eine Vielzahl von Unternehmen treibt die Einführung von Impfungen voran, die das Immunsystem bei der Bekämpfung spezifischer Tumore von Patienten unterstützen sollen. Krebszellen sind mit mutierten Proteinen, sogenannten „Neoantigenen“, bedeckt, die in gesunden Zellen nicht vorkommen. Personalisierte Krebsimpfstoffe trainieren das Immunsystem, die einzigartigen Neoantigene eines Patienten zu erkennen und dann die Krebszellen zu finden und zu zerstören.“
https://www.freethink.com/health/personalized-cancer-vaccines?fbclid=PAZXh0bgNhZW0BMQABpkHLlquTcD9Hac94lV-7DUqgziGkhaL8MgrqpoFVTcbqjsXi4gVMe–_bQ_aem_Ach8SSsGV_keOT5POil20K4t2BTscwa-FrEfwz1nNw0IFeCK2S-R95-upld9EbFwzvg
2 Kommentare
Submission Statement:
“The latest: For personalized cancer vaccines to work, they need to target the right neoantigens and trigger a strong immune response, all while being safe and tolerable for patients. After years of mixed results, it seems like the pieces are all starting to come together.
“Because cancers arise from our own cells, it is much harder for the immune system to distinguish proteins in cancer cells as foreign compared with proteins in pathogens like viruses,” said Vinod Balachandran, a pancreatic cancer surgeon-scientist at Memorial Sloan Kettering Cancer Center.
“But important advances in cancer biology, the development of novel biotechnologies, and genomic sequencing now make it possible to design vaccines that can tell the difference,” he continued.
Moderna researchers used AACR’s annual meeting to present results from an ongoing trial of an in-development cancer vaccine, called mRNA-4157, which had previously shown promise at preventing recurrence of melanoma.
In the new trial, Moderna is testing the vaccine against a different kind of cancer, called HPV-negative head and neck squamous cell carcinoma (HPV- HNSCC). This cancer has a five-year survival rate of less than 50%. In all 22 trial participants, the cancer could not be removed via surgery and was either recurrent or had spread to other parts of their body.
During the trial, patients received infusions of mRNA-4157 combined with pembrolizumab (brand name Keytruda), an FDA-approved cancer immunotherapy. According to Moderna, 14 people experienced some level of disease control, with two going into complete remission.“
Having known many people over the years that have died of various cancers that could have used this treatment, I’m not sure “having a moment” is the appropriate headline.